ObsEva SA Logo

ObsEva SA

Developed novel therapeutics for women's reproductive health and pregnancy.

OBSN | SW

Overview

Corporate Details

ISIN(s):
CH1260041939
LEI:
549300PNZ0UEJVKN1618
Country:
Switzerland
Address:
CHEMIN DES AULX 12, 1228 PLAN-LES-OUATES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ObsEva SA is a clinical-stage biopharmaceutical company that was focused on the development and commercialization of novel therapeutics for women's reproductive health and pregnancy. Founded in 2012, the company's research centered on treatments for serious conditions from conception to birth, such as preterm labor. In February 2024, the company announced it was winding down its operations. Note: The provided sources contain conflicting information, identifying the company's industry as biopharmaceutical, not financial data services, and including unrelated content from a sports streaming website.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ObsEva SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ObsEva SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ObsEva SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-17 N/A Non-Executive member Buy None 2,058.00 CHF
2022-03-16 N/A Non-Executive member Buy None 27,010.00 CHF
2022-03-15 N/A Non-Executive member Buy None 23,642.00 CHF
2022-02-08 N/A Non-Executive member Buy None 64,161.00 CHF
2022-02-01 N/A Non-Executive member Buy None 70,716.00 CHF
2022-01-24 N/A Non-Executive member Buy None 69,748.00 CHF
2022-01-11 N/A Non-Executive member Buy None 183,535.00 CHF
2022-01-10 N/A Non-Executive member Buy None 177,643.00 CHF

Peer Companies

Benitec Biopharma Inc. Logo
Develops ddRNAi gene therapies to silence genes causing chronic, life-threatening diseases.
United States of America
BNTC
BeOne Medicines Ltd. Logo
Develops innovative and accessible cancer treatments for patients worldwide.
United States of America
ONC
BGM Group Ltd. Logo
A pharma holding co. making APIs & TCM derivatives via bio-fermentation and extraction.
United States of America
BGM
Bicara Therapeutics Inc. Logo
Developing first-in-class, dual-action bifunctional therapies for solid tumor patients.
United States of America
BCAX
BICYCLE THERAPEUTICS PLC Logo
Developing novel bicyclic peptide medicines to precisely target hard-to-treat cancers.
United States of America
BCYC
BIFIDO. Co. Ltd Logo
Biotech firm specializing in microbiome R&D for functional foods and cosmeceuticals.
South Korea
238200
BioAge Labs, Inc. Logo
Develops therapies for metabolic diseases like obesity by targeting the biology of human aging.
United States of America
BIOA
BioArctic Logo
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
Sweden
BIOA
BioAtla, Inc. Logo
Developing safer, conditionally active antibody therapies for solid tumor cancers.
United States of America
BCAB
BioCardia, Inc. Logo
Developing regenerative cell therapies for cardiovascular and pulmonary diseases.
United States of America
BCDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.